Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, and welcome to the BioXcel Therapeutics Third ...

A psychiatrist, Dr Yennusom Maalug, has cautioned that, untreated bipolar or mood disorders could lead to serious mental and ...

The hospital will provide inpatient treatment for people who suffer from behavioral health conditions such as depression, ...

Bioxcel Therapeutics ( (BTAI) ) has released its Q3 earnings. Here is a breakdown of the information Bioxcel Therapeutics presented to its ...

Vincent O'Neill; Executive Vice President, Chief of Product Development and Medical Officer; BioXcel Therapeutics Inc Alec Stranahan; Analyst; BofA Securities, Inc.

The unique stress that older mothers of vulnerable adult children experience over the holidays is often overlooked. Here's ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

WEST JORDAN, Utah — A suspect was taken to the hospital after a police response escalated to a shooting early Sunday morning.

Bipolar disorders are currently divided into 4 entities: bipolar I, bipolar II, cyclothymic disorder, and bipolar disorder not otherwise specified, as described in the fourth edition of the ...

YouGov poll reveals less than half of Scots think public understanding about severe mental illness is better now than it was ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...